Dr. Uma M. Borate, MD
Hematology (Hematology (Internal Medicine) Physician)
- Medicare participating
At a glance
- Years since graduation
- 23
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 159
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
OH license 35.140779
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ohio State University State Health System Columbus, OH
- Fairfield Medical Center Lancaster, OH
Medical groups
- Osu Internal Medicine LLC (1,161 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 159
- Services billed
- 582
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 143 | 37 |
| Established patient office or other outpatient visit, 30-39 minutes | 138 | 66 |
| Established patient office or other outpatient visit, 40-54 minutes | 20 | 20 |
| New patient office or other outpatient visit, 60-74 minutes | 19 | 19 |
| Hospital discharge day management, more than 30 minutes | 16 | 15 |
| Established patient office or other outpatient visit, 20-29 minutes | 12 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Venclexta (venetoclax) | 72 |
| Jakafi (ruxolitinib phosphate) | 32 |
| Sprycel (dasatinib) | 29 |
| Onureg (azacitidine) | 14 |
| Ojjaara (momelotinib dihydrochloride) | 13 |
| Scemblix (asciminib hydrochloride) | 12 |
| Revlimid (lenalidomide) | 11 |
| Iclusig (ponatinib hcl) | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 15 companies reported 62 payments worth $57,005 in total to this clinician.
| Daiichi Sankyo Inc. | $10,610 |
|---|---|
| Syndax Pharmaceuticals, Inc. | $8,748 |
| Incyte Corporation | $8,633 |
| AbbVie Inc. | $8,100 |
| Geron Corporation | $5,798 |
| Sumitomo Pharma America, Inc. | $3,440 |
| Astellas Pharma US Inc | $2,927 |
| Janssen Scientific Affairs, LLC | $2,806 |
| Consulting Fee | $49,991 |
|---|---|
| Travel and Lodging | $5,069 |
| Food and Beverage | $1,946 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Incyte Corporation Oct 24, 2025 | Consulting Fee | $7,193 |
| Daiichi Sankyo Inc. May 7, 2025 | Consulting Fee Vanflyta · ONCOLOGY | $6,860 |
| Syndax Pharmaceuticals, Inc. Jul 10, 2025 | Consulting Fee REVUFORJ · HEMATOLOGY-ONCOLOGY | $4,250 |
| AbbVie Inc. Feb 19, 2025 | Consulting Fee | $4,050 |
| AbbVie Inc. Jul 2, 2025 | Consulting Fee | $4,050 |
| Sumitomo Pharma America, Inc. Jul 24, 2025 | Consulting Fee | $3,440 |
| Astellas Pharma US Inc Jan 22, 2025 | Consulting Fee Xospata · Oncology | $2,776 |
| Janssen Scientific Affairs, LLC Sep 23, 2025 | Consulting Fee | $2,503 |
| Geron Corporation Sep 22, 2025 | Consulting Fee RYTELO · MYELODYSPLASTIC SYNDROME | $2,400 |
| Syndax Pharmaceuticals, Inc. Aug 7, 2025 | Consulting Fee REVUFORJ · HEMATOLOGY-ONCOLOGY | $2,400 |
All 35 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Genentech USA, Inc. Dec 6, 2025 | Consulting Fee Venclexta · BioOncology | $1,640 |
| Genentech USA, Inc. Dec 6, 2025 | Travel and Lodging Venclexta · BioOncology · travel to Orlando, FL | $363 |
| Genentech USA, Inc. Dec 6, 2025 | Travel and Lodging Venclexta · BioOncology · travel to Orlando, FL | $144 |
| Incyte Corporation Oct 24, 2025 | Consulting Fee | $7,193 |
| Incyte Corporation Oct 24, 2025 | Travel and Lodging travel to Wilmington, DE | $740 |
| Incyte Corporation Oct 24, 2025 | Travel and Lodging travel to Wilmington, DE | $329 |
| Incyte Corporation Oct 24, 2025 | Travel and Lodging travel to Wilmington, DE | $70.90 |
| Incyte Corporation Oct 24, 2025 | Travel and Lodging travel to Wilmington, DE | $36.00 |
| Incyte Corporation Oct 23, 2025 | Travel and Lodging travel to Wilmington, DE | $131 |
| Incyte Corporation Oct 23, 2025 | Travel and Lodging travel to Wilmington, DE | $64.90 |
| Janssen Scientific Affairs, LLC Sep 23, 2025 | Consulting Fee | $2,503 |
| Geron Corporation Sep 22, 2025 | Consulting Fee RYTELO · MYELODYSPLASTIC SYNDROME | $2,400 |
| Geron Corporation Sep 22, 2025 | Travel and Lodging RYTELO · MYELODYSPLASTIC SYNDROME · travel to HOUSTON, TX | $48.64 |
| Syndax Pharmaceuticals, Inc. Aug 7, 2025 | Consulting Fee REVUFORJ · HEMATOLOGY-ONCOLOGY | $2,400 |
| Sumitomo Pharma America, Inc. Jul 24, 2025 | Consulting Fee | $3,440 |
| Syndax Pharmaceuticals, Inc. Jul 10, 2025 | Consulting Fee REVUFORJ · HEMATOLOGY-ONCOLOGY | $4,250 |
| Syndax Pharmaceuticals, Inc. Jul 10, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to DENVER, CO · in-kind | $980 |
| Syndax Pharmaceuticals, Inc. Jul 10, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to DENVER, CO · in-kind | $377 |
| Syndax Pharmaceuticals, Inc. Jul 10, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to DENVER, CO | $141 |
| Syndax Pharmaceuticals, Inc. Jul 10, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to DENVER, CO · in-kind | $126 |
| AbbVie Inc. Jul 2, 2025 | Consulting Fee | $4,050 |
| Geron Corporation May 21, 2025 | Consulting Fee RYTELO · MYELODYSPLASTIC SYNDROME | $1,600 |
| Daiichi Sankyo Inc. May 7, 2025 | Consulting Fee Vanflyta · ONCOLOGY | $6,860 |
| Daiichi Sankyo Inc. May 7, 2025 | Consulting Fee Vanflyta · ONCOLOGY | $2,058 |
| Daiichi Sankyo Inc. Apr 9, 2025 | Travel and Lodging Vanflyta · ONCOLOGY · travel to BASKING RIDGE, NJ · in-kind | $66.82 |
| Daiichi Sankyo Inc. Apr 9, 2025 | Travel and Lodging Vanflyta · ONCOLOGY · travel to BASKING RIDGE, NJ · in-kind | $64.27 |
| Daiichi Sankyo Inc. Apr 9, 2025 | Travel and Lodging Vanflyta · ONCOLOGY · travel to BASKING RIDGE, NJ · in-kind | $38.31 |
| Daiichi Sankyo Inc. Apr 9, 2025 | Travel and Lodging Vanflyta · ONCOLOGY · travel to BASKING RIDGE, NJ · in-kind | $17.00 |
| Daiichi Sankyo Inc. Feb 26, 2025 | Travel and Lodging Vanflyta · ONCOLOGY · travel to MIAMI, FL · in-kind | $689 |
| Daiichi Sankyo Inc. Feb 26, 2025 | Travel and Lodging Vanflyta · ONCOLOGY · travel to MIAMI, FL · in-kind | $642 |
| AbbVie Inc. Feb 19, 2025 | Consulting Fee | $4,050 |
| Genmab U.S., Inc. Feb 7, 2025 | Consulting Fee Epkinly · Oncology | $785 |
| E.r. Squibb & Sons, L.l.c. Jan 23, 2025 | Consulting Fee | $2,388 |
| Astellas Pharma US Inc Jan 22, 2025 | Consulting Fee Xospata · Oncology | $2,776 |
| Geron Corporation Jan 8, 2025 | Consulting Fee RYTELO · MYELODYSPLASTIC SYNDROME | $1,600 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 27 industry-funded studies in 2025, from 13 companies. The companies reported $9,315,053 in research payments for these studies, mostly to the institutions running them.
- Inflammation Modification to Prevent Leukemic Progression of Clonal Cytopenias of Unknown Signicance Trial (IMPACT)
Novartis Pharmaceuticals Corporation - A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplasti…
Taiho Oncology, Inc. - A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AM…
Astellas Pharma Global Development - A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low…
Celgene Corporation - A20-256;Venclexta;Blister Card: ABT-199 100mg Tablet, 1x8 Tablets
AbbVie Inc. - Phase II study of clinical efficacy of venetoclax in combination with azacitidine in patients with therapy related myelodysplastic syndrome (t-MDS)
AbbVie Inc. - A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Sumitomo Pharma America, Inc. · Recruiting · NCT04988555 - A20-256;Venclexta;Blister Card: ABT-199 50mg Film-coated Tablet 1x8, 8 Tablets
AbbVie Inc. - A Phase I/II, open-label, multi-center study evaluating the safety and efficacy of Ruxolitinib and CPX-351 in combination for the treatment of Secondary Acute Myeloid Leukemia Transformed from Myeloproliferative Neopl…
Incyte Corporation - A Phase Ib, multicenter, open-label platform study of select drug combinations in adult patients with lower risk (very low, low, or intermediate risk) myelodysplastic syndrome
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.